Nightingale Ginah, Hajjar Emily, Pizzi Laura T, Wang Margaret, Pigott Elizabeth, Doherty Shannon, Prioli Katherine M, Swartz Kristine, Chapman Andrew E
Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, United States.
Department of Pharmacy Practice, Jefferson College of Pharmacy, Thomas Jefferson University, Philadelphia, PA, United States.
J Geriatr Oncol. 2017 Jul;8(4):296-302. doi: 10.1016/j.jgo.2017.04.005. Epub 2017 May 13.
Medication-related problems (MRP) affecting older adults are a significant healthcare concern and account for billions in medication-related morbidity. Cancer therapies can increase the prevalence of MRP. The objective of this study was to test the feasibility and effectiveness of implementing a pharmacist-led individualized medication assessment and planning (iMAP) intervention on the number and prevalence of MRP.
This prospective pilot study enrolled oncology outpatients aged ≥65years. Intervention feasibility encompassed recommendation acceptance rate and intervention delivery time. The intervention was facilitated by pharmacists where patients received comprehensive medication management at baseline and at the 30- and 60-day follow-up.
Forty-eight eligible patients enrolled and 41 patients (85.4%) were included in the analysis. Mean age was 79.1years [range 65-101]; 66% women, 83% Caucasian, mean comorbidity count was 7.76. Forty-six percent of the pharmacist recommendations were accepted and the prevalence of MRP at baseline versus 60-day follow-up decreased by 20.5%. The average time to conduct the initial session was 22min versus 15min for the follow-up sessions. Resources needed included a tracking system for scheduling follow-up calls and a database for tracking acceptance of recommendations. A total of 123 MRP were identified in 95% of patients (N=39) with a mean of 3 MRP per patient. The mean reduction in number of MRP (3 at baseline versus 1.6 at 60-day follow-up) was 45.5%.
The pharmacist-led iMAP intervention was feasible and effective at reducing MRP. Additional inter-professional medication safety based interventions measuring patient-reported outcomes are still needed.
影响老年人的药物相关问题(MRP)是一个重大的医疗保健问题,在药物相关发病率方面造成了数十亿美元的损失。癌症治疗会增加MRP的发生率。本研究的目的是测试实施由药剂师主导的个体化药物评估与规划(iMAP)干预措施对MRP数量和发生率的可行性和有效性。
这项前瞻性试点研究纳入了年龄≥65岁的肿瘤门诊患者。干预措施的可行性包括建议接受率和干预实施时间。干预由药剂师推动,患者在基线时以及随访30天和60天时接受全面的药物管理。
48名符合条件的患者入组,41名患者(85.4%)纳入分析。平均年龄为79.1岁[范围65 - 101岁];66%为女性,83%为白种人,平均合并症数为7.76种。药剂师的建议有46%被接受,基线时与60天随访时MRP的发生率下降了20.5%。进行初次会诊的平均时间为22分钟,随访会诊为15分钟。所需资源包括用于安排随访电话的跟踪系统和用于跟踪建议接受情况的数据库。在95%的患者(N = 39)中总共识别出123个MRP,每位患者平均有3个MRP。MRP数量的平均减少量(基线时为3个 vs 60天随访时为1.6个)为45.5%。
由药剂师主导的iMAP干预措施在减少MRP方面是可行且有效的。仍然需要基于跨专业药物安全的其他干预措施来衡量患者报告的结果。